Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. NAVN
5. CNC
6. KFY
7. ABBV
8. MU
9. DPZ
10. PLTR

Go back to Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

December 2, 2024 4:30 PM EST

Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patients In 16 patients JANX007 displayed: High PSA response rates: 100% achieved best PSA50 declines Deep PSA declines: 63% achieved best PSA90 declines; 31% achieved best PSA99 declines Durable PSA response at 12 weeks: 75% maintained PSA50 declines; 50% maintained PSA90 declines Encouraging anti-tumor activity: 50% ORR (4/8) and 63% DCR (5/8) Well-tolerated safety profile: CRS and TRAEs primarily limited to cycle 1 and grades 1 and 2; Maximum tolerable dose has not yet... More